Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on July 19, 2019, regarding events occurring on July 18, 2019. The filing discloses the appointment of a new Chief Financial Officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of Michael Rossi as Chief Financial Officer, effective July 18, 2019. This replaces the prior leadership structure for the finance function.
Guidance, Outlook, and Compensation Details
Management commentary is limited to the announcement of the new CFO. The filing details the following compensation terms for Mr. Rossi:
- Base Salary: $340,000 annually.
- Term: One year, automatically extending for one additional year unless terminated by notice.
- Cash Incentive: Eligible for up to 50% of base salary commencing in fiscal year 2020, subject to Board-determined objectives.
- Equity Grant:
- Stock Option: 111,842 shares at an exercise price of $1.78, vesting in four equal annual installments.
- Restricted Stock Units (RSUs): Target of 47,753 shares with a market condition based on relative total shareholder return versus the NASDAQ Biotechnology index. The award ranges from 0% (below 20th percentile) to 150% (at or above 75th percentile) of the target.
- Severance: Provisions for payments upon termination without cause, for good reason, death, disability, or change-in-control, including accrued salary, vacation, and potential acceleration of vesting.
Investor Verification Checklist
- Verify the impact of the new CFO's experience on the company's financial strategy and operational efficiency.
- Review the specific performance metrics for the cash incentive plan once established by the Board.
- Monitor the vesting schedule and market condition performance of the RSU grant relative to the NASDAQ Biotechnology index.
- Assess the potential dilution impact of the 111,842 stock options and up to 71,629 RSUs (150% of target).